ONCOLOGY

Provide earlier intervention strategies for the prevention of disease progression

Disclaimer: InBody devices should be used as an adjunct tool for clinical decision making and are not intended to diagnose or treat any diseases.

ONCOLOGY

Provide earlier intervention strategies for the prevention of disease progression

Disclaimer: InBody devices should be used as an adjunct tool for clinical decision making and are not intended to diagnose or treat any diseases.

Why is body composition analysis an effective tool for cancer treatment?

InBody devices provide a quick, easy, non-invasive, and precise method for assessing health risks and the effects of interventions. In less than 60 seconds, the InBody Test can be used to:

  • Monitor changes in body composition to improve patient outcomes and quality of life
  • Assess cellular integrity to evaluate malnutrition risk
  • Identify fluid imbalances and risk of lymphedema for earlier intervention

MUSCLE-FAT ANALYSIS

Set strategies to promote muscle maintenance

Disease onset and progression can cause changes in body composition despite weight maintenance, which would be overlooked by BMI. Assessing muscle-fat balance allows medical professionals to monitor the effects of treatment to prevent worsening outcomes.

Cancer patients often experience significant changes in body composition, namely muscle loss, fat gain, or a combination of these factors. When these occur simultaneously, weight may not change significantly, making BMI a poor indicator of physiological change. By monitoring objective measures of muscle and fat mass, medical professionals can assess physiological changes and symptoms associated with malnutrition and cancer cachexia. Additional outputs of basal metabolic rate (BMR) aid nutritionists in setting strategies to promote muscle maintenance and management of fat gain/loss. Tracking the outcomes of these programs provides oncologists with the tools to provide more direct treatment strategies to improve quality of life and patient outcomes.

WHOLE BODY PHASE ANGLE

Track effect of immunotherapies by monitoring cell health

Cancer and cancer treatments cause damage to cells, compromising immune function and reducing cellular integrity. By tracking phase angle, oncologists can monitor the cellular health of patients for earlier detection of symptoms/disease progression.

Phase angle, a measure of how the cells respond to the electrical currents used to measure body composition, reflects cell membrane integrity and has been linked to survival in various oncological populations. When cells are healthy, they are better able to resist these currents utilized by the InBody, resulting in a higher phase angle. Because cancer and various treatment modalities cause damage to the cells before the loss of muscle and fat mass, this decrease in phase angle can be linked to cancer-cachexia related malnutrition as well as other medical risks/conditions. By monitoring segmental and whole body phase angle, oncologists can pinpoint the risk of specific comorbidities, track the effects of immunotherapies more precisely, and provide earlier intervention strategies for the prevention of disease progression.

WHOLE BODY AND SEGMENTAL ECW/TBW WATER ANALYSIS

Identify localized fluid to detect cancer-related circulation issues

Cancer leads to muscle loss and compromises organs and cellular functions that can lead to systemic inflammation or edema. InBody’s technology is able to precisely track fluid changes across the body to understand the cause of imbalanced fluid levels.

InBody effectively distinguishes water in the intracellular (ICW; within the tissues) and extracellular (ECW; within the blood and interstitial fluids) compartments that make up total body water (TBW). The Edema Index, based on the ratio between ECW and TBW (ECW/TBW), can be used to distinguish fluid imbalances resulting from malnutrition or edema. Managing increases in Edema Index is a priority for improving patient outcomes.

Due to the high water content of muscles, loss of muscle mass causes a reduction in ICW and results in an increased Edema Index. Thus, the Edema Index can be used to identify malnutrition separately from other disease-related fluid imbalances.

Since cancer symptoms are associated with increased systemic inflammation, progressing fluid imbalances are linked to poor patient outcomes. The Edema Index can be used to identify and monitor long-term fluid retention, which causes cellular stress and may lead to comorbidities such as renal or cardiac dysfunction. By tracking whole-body ECW/TBW, efficacy of anti-inflammatory drugs can be assessed and used to guide clinical decisions. Additionally, segmental Edema Index scores are important for identifying localized fluid imbalances in the limbs or trunk, aiding in the earlier detection of cancer-related lymphedema or circulation issues.

Learn More

MUSCLE-FAT ANALYSIS

Set strategies to promote muscle maintenance

Disease onset and progression can cause changes in body composition despite weight maintenance, which would be overlooked by BMI. Assessing muscle-fat balance allows medical professionals to monitor the effects of treatment to prevent worsening outcomes.

Cancer patients often experience significant changes in body composition, namely muscle loss, fat gain, or a combination of these factors. When these occur simultaneously, weight may not change significantly, making BMI a poor indicator of physiological change. By monitoring objective measures of muscle and fat mass, medical professionals can assess physiological changes and symptoms associated with malnutrition and cancer cachexia. Additional outputs of basal metabolic rate (BMR) aid nutritionists in setting strategies to promote muscle maintenance and management of fat gain/loss. Tracking the outcomes of these programs provides oncologists with the tools to provide more direct treatment strategies to improve quality of life and patient outcomes.

WHOLE BODY PHASE ANGLE

Track effect of immunotherapies by monitoring cell health

Cancer and cancer treatments cause damage to cells, compromising immune function and reducing cellular integrity. By tracking phase angle, oncologists can monitor the cellular health of patients for earlier detection of symptoms/disease progression.

Phase angle, a measure of how the cells respond to the electrical currents used to measure body composition, reflects cell membrane integrity and has been linked to survival in various oncological populations. When cells are healthy, they are better able to resist these currents utilized by the InBody, resulting in a higher phase angle. Because cancer and various treatment modalities cause damage to the cells before the loss of muscle and fat mass, this decrease in phase angle can be linked to cancer-cachexia related malnutrition as well as other medical risks/conditions. By monitoring segmental and whole body phase angle, oncologists can pinpoint the risk of specific comorbidities, track the effects of immunotherapies more precisely, and provide earlier intervention strategies for the prevention of disease progression.

WHOLE BODY AND SEGMENTAL ECW/TBW WATER ANALYSIS

Identify localized fluid to detect cancer-related circulation issues

Cancer leads to muscle loss and compromises organs and cellular functions that can lead to systemic inflammation or edema. InBody’s technology is able to precisely track fluid changes across the body to understand the cause of imbalanced fluid levels.

InBody effectively distinguishes water in the intracellular (ICW; within the tissues) and extracellular (ECW; within the blood and interstitial fluids) compartments that make up total body water (TBW). The Edema Index, based on the ratio between ECW and TBW (ECW/TBW), can be used to distinguish fluid imbalances resulting from malnutrition or edema. Managing increases in Edema Index is a priority for improving patient outcomes.

Due to the high water content of muscles, loss of muscle mass causes a reduction in ICW and results in an increased Edema Index. Thus, the Edema Index can be used to identify malnutrition separately from other disease-related fluid imbalances.

Since cancer symptoms are associated with increased systemic inflammation, progressing fluid imbalances are linked to poor patient outcomes. The Edema Index can be used to identify and monitor long-term fluid retention, which causes cellular stress and may lead to comorbidities such as renal or cardiac dysfunction. By tracking whole-body ECW/TBW, efficacy of anti-inflammatory drugs can be assessed and used to guide clinical decisions. Additionally, segmental Edema Index scores are important for identifying localized fluid imbalances in the limbs or trunk, aiding in the earlier detection of cancer-related lymphedema or circulation issues.

Get In Touch

Are you wondering if a professional InBody device is right for you? We partner you with an InBody specialist that understands your industry and unique needs.

Get in touch today!

Get In Touch

Are you wondering if a professional InBody device is right for you? We partner you with an InBody specialist that understands your industry and unique needs.

Get in touch today!